Document Detail


The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment.
MedLine Citation:
PMID:  8485026     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The pharmacokinetics of the 5-HT3 receptor antagonist ondansetron were investigated following a single 8 mg intravenous dose given over 5 min in 19 patients with varying degrees of hepatic impairment and in six young healthy subjects. In comparison with the healthy controls, the patients with severe hepatic impairment had a lower mean plasma clearance (96 ml min-1 vs 478 ml min-1) and increased AUC (1383 ng ml-1 h vs 279 ng ml-1 h) and t1/2 (21 h vs 3.6 h). These differences were all statistically significant (P < 0.001). The corresponding values for patients with mild or moderate hepatic impairment fell between these extremes. Vss was greater in all patient groups than the control group, but the magnitude of the change was smaller than for the other parameters and did not reflect the increasing severity of hepatic impairment. There were no significant changes in Cmax. There were no drug-related adverse events in the patients studied. It is recommended that the dosing frequency of ondansetron be limited to once daily in patients with severe hepatic impairment.
Authors:
J C Blake; J L Palmer; N A Minton; A K Burroughs
Related Documents :
21155166 - Correlations between obstetric complications and neurological soft signs in tunisian pa...
21314496 - The value of the occlusion test in decompensating exophorias and intermittent exotropias.
21373936 - Effects of breathing training on voluntary hypo- and hyperventilation in patients with ...
9876806 - Predictive performance of ten equations for estimating creatinine clearance in cardiac ...
21960416 - Renal sympathetic denervation for treatment of electrical storm: first-in-man experience.
8893586 - Kartagener's syndrome: clinical presentation and cardiosurgical aspects.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  35     ISSN:  0306-5251     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  1993 Apr 
Date Detail:
Created Date:  1993-06-10     Completed Date:  1993-06-10     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  441-3     Citation Subset:  IM    
Affiliation:
University Department of Medicine, Royal Free Hospital and School of Medicine, London.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Female
Half-Life
Humans
Infusions, Intravenous
Liver Diseases / blood,  metabolism*
Male
Middle Aged
Ondansetron / blood,  pharmacokinetics*
Chemical
Reg. No./Substance:
99614-02-5/Ondansetron
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effect of tocainide on theophylline metabolism.
Next Document:  The pharmacokinetics of quinine in patients with hepatitis.